Variable | Biochemical Recurrence-Free Survival | |||
---|---|---|---|---|
Univariate analysis | Multivariate analysis | |||
P Value | HR | P Value | HR | |
Age at diagnosis (years) ≤70 vs >70 | 0.339 | ―― | 0.147 | ―― |
Gland volume (mL) ≤33 vs >33 | 0.047 | 3.668 | 0.016 | 8.336 |
MAB Continuous vs Intermittent | 0.031 | 1.492 | 0.018 | 3.217 |
PPB yes vs no | 0.001 | 2.888 | <0.001 | 5.126 |
Clinical stage ≤ T2c vs ≥T3a | 0.041 | 4.737 | 0.013 | 6.142 |
Gleason score ≤7 vs ≥8 | 0.013 | 5.711 | 0.022 | 3.463 |
PSA at diagnosis (ng/mL) ≤10 vs 10~20 vs ≥20 | 0.019 | 2.622 | 0.001 | 6.334 |
Memorial Sloan-Kettering risk classification 2~3 IS vs 1 HS vs 2 HS | 0.027 | 1.772 | 0.009 | 3.643 |
PSA nadir (ng/mL) ≤1 vs >1 | 0.041 | 1.323 | 0.016 | 6.993 |
Time to PSA nadir (months) ≤3 vs >3 | 0.032 | 2.116 | 0.011 | 5.843 |
PSA doubling time (months) ≤12 vs >12 | 0.048 | 1.863 | 0.014 | 6.132 |
PSA decrease (%) <90 vs ≥90 | 0.006 | 3.677 | <0.001 | 9.385 |